Host |
Mouse + Rabbit |
Clone |
B-A38 + SP4 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Multiple myeloma, bone marrow, tonsil |
Dilution |
- |
Isotype |
IgG1 + IgG |
Localization |
Cell membrane (CD138), nucleus (Cyclin D1) |
CD138 + Cyclin D1
|
Biocare Medical |
B-A38 + SP4 |
6 ml |
Ready-to-use |
CE/IVD |
API3193DSAA |
-
|
Host |
Mouse |
Clone |
BNI3 |
Format |
Purified |
Method |
F, FL |
Isotype |
Mouse IgG2a |
Immunogen |
Human CTLA-4/human IgG heavy chain fusion protein |
CD152 (CTLA4, Cytolytic T-lymphocyte-associated Antigen 4)
|
Zytomed Systems GmbH |
BNI3 |
200 µg |
Purified |
RUO |
603-1614 |
-
|
Host |
Mouse |
Clone |
BNI3 |
Format |
Purified |
Method |
FL |
Isotype |
Mouse IgG2a |
Immunogen |
Human CTLA-4/human IgG heavy chain fusion protein |
CD152 (CTLA4, Cytolytic T-lymphocyte-associated Antigen 4) - PE
|
Zytomed Systems GmbH |
BNI3 |
100 Tests |
Purified |
RUO |
603-1619E |
-
|
Host |
Mouse |
Clone |
EDHu-1 |
Format |
Purified |
Method |
F, P, WB, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Leucocytes harvested from pleural cavity of patients with idiopathic spontaneous pneumothorax |
CD163
|
Zytomed Systems GmbH |
EDHu-1 |
200 µg |
Purified |
RUO |
603-1623 |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil, placenta |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cell membrane |
CD163
|
Biocare Medical |
10D6 |
0.1 ml |
Concentrate |
CE/IVD |
CM353AK |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil, placenta |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 |
Localization |
Cell membrane |
CD163
|
Biocare Medical |
10D6 |
1 ml |
Concentrate |
CE/IVD |
CM353CK |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG |
Localization |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
1 ml |
Concentrate |
CE/IVD |
MOB460 |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG |
Localization |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB460-01 |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:50 |
Isotype |
Mouse IgG |
Localization |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB460-05 |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG |
Localization |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
6 ml |
Ready-to-use |
CE/IVD |
PDM579 |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG |
Localization |
Cell Membrane |
CD163
|
Diagnostic Biosystems |
10D6 |
25 ml |
Ready-to-use |
CE/IVD |
PDM579-25 |
-
|
Host |
Mouse |
Clone |
10D6 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil, placenta |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Cell membrane |
CD163
|
Biocare Medical |
10D6 |
6 ml |
Ready-to-use |
CE/IVD |
PM353AA |
-
|
Host |
Monospecific Mouse |
Clone |
ZM29 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Liver. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human CD163 fragment (around aa 43-196) |
Localization |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
1 ml |
Concentrate |
CE/IVD |
Z2361ML |
-
|
Host |
Monospecific Mouse |
Clone |
ZM29 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Liver. |
Dilution |
- |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human CD163 fragment (around aa 43-196) |
Localization |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
7 ml |
Ready-to-use |
CE/IVD |
Z2361MP |
-
|
Host |
Monospecific Mouse |
Clone |
ZM29 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Liver. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human CD163 fragment (around aa 43-196) |
Localization |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
0.5 ml |
Concentrate |
CE/IVD |
Z2361MS |
-
|
Host |
Monospecific Mouse |
Clone |
ZM29 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Pretreatment |
Citrate or EDTA |
Positive control |
Liver. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant human CD163 fragment (around aa 43-196) |
Localization |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
0.1 ml |
Concentrate |
CE/IVD |
Z2361MT |
-
|
Host |
Mouse |
Clone |
BRIC111 |
Format |
Purified |
Method |
F |
Isotype |
Mouse IgG1 |
Immunogen |
Human Tn red blood cells |
CD175
|
Zytomed Systems GmbH |
BRIC111 |
200 µg |
Purified |
RUO |
603-1631 |
-
|
Host |
Mouse |
Clone |
ZM360 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
Localization |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
1 ml |
Concentrate |
CE/IVD |
Z2736ML |
-
|
Host |
Mouse |
Clone |
ZM360 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
Localization |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
7 ml |
Concentrate |
CE/IVD |
Z2736MP |
-
|
Host |
Mouse |
Clone |
ZM360 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
Localization |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
0.5 ml |
Concentrate |
CE/IVD |
Z2736MS |
-
|
Host |
Mouse |
Clone |
ZM360 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
IgG2b /κ |
Immunogen |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
Localization |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
0.1 ml |
Concentrate |
CE/IVD |
Z2736MT |
-
|
Host |
Mouse |
Clone |
DX11 |
Format |
Purified |
Method |
IP, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1)
|
Zytomed Systems GmbH |
DX11 |
200 µg |
Purified |
RUO |
603-1726 |
-
|
Host |
Mouse |
Clone |
DX11 |
Format |
Purified |
Method |
IP, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1)
|
Zytomed Systems GmbH |
DX11 |
100 µg |
Purified |
RUO |
603-1728 |
-
|
Host |
Mouse |
Clone |
DX11 |
Format |
Purified |
Method |
IP, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1) (Azide Free)
|
Zytomed Systems GmbH |
DX11 |
1 mg |
Purified |
RUO |
603-1732F |
-
|
Host |
Mouse |
Clone |
DX11 |
Format |
Purified |
Method |
IP, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1) (Low Endotoxin)
|
Zytomed Systems GmbH |
DX11 |
500 µg |
Purified |
RUO |
603-1727 |
-
|
Host |
Mouse |
Clone |
DX11 |
Format |
Purified |
Method |
IP, FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1) - Biotin
|
Zytomed Systems GmbH |
DX11 |
100 µg |
Purified |
RUO |
603-1729B |
-
|
Host |
Rabbit |
Clone |
polyclonal |
Format |
Purified |
Method |
IHC(P), WB |
Pretreatment |
Citrate |
Positive control |
Mouse brain tissue |
Dilution |
0.5 - 1 µg/ml (~ 1:1.000 - 1:2.000) |
Isotype |
Rabbit IgG |
Immunogen |
A peptide corresponding to a 16 amino acid sequence from near the centre of Human CD273. |
CD273 (PD-L2)
|
Zytomed Systems GmbH |
polyclonal |
100 µg (100 µl) |
Purified |
RUO |
603-2393 |
-
|
Host |
Rabbit |
Clone |
SP98 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil, reactive lymph node |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human CD278 |
Localization |
Cell Membrane |
CD278
|
Zytomed Systems GmbH |
SP98 |
0.5 ml |
Concentrate |
RUO |
509-3982 |
-
|
Host |
Rabbit |
Clone |
SP98 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Tonsil, reactive lymph node |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human CD278 |
Localization |
Cell Membrane |
CD278
|
Zytomed Systems GmbH |
SP98 |
1 ml |
Concentrate |
RUO |
509-3984 |
-
|
Host |
Mouse |
Clone |
VU-ID9 |
Format |
Purified |
Method |
F, P, WB, IP, FL |
Pretreatment |
Trypsin |
Positive control |
Large Bowel |
Dilution |
1:200 (P) |
Isotype |
Mouse IgG1 |
Immunogen |
HG9 cell line (small cell lung carcinoma) |
CD326
|
Zytomed Systems GmbH |
VU-ID9 |
200 µg |
Purified |
RUO |
603-2331 |
-
|
Host |
Mouse |
Clone |
DCS.120+DCS.121 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG2a |
Localization |
Nuclear Membrane |
CDC25A
|
Diagnostic Biosystems |
DCS.120+DCS.121 |
1 ml |
Concentrate |
CE/IVD |
MOB337 |
-
|
Host |
Mouse |
Clone |
DCS.120+DCS.121 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG2a |
Localization |
Nuclear Membrane |
CDC25A
|
Diagnostic Biosystems |
DCS.120+DCS.121 |
0.1 ml |
Concentrate |
CE/IVD |
MOB337-01 |
-
|
Host |
Mouse |
Clone |
DCS.120+DCS.121 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG2a |
Localization |
Nuclear Membrane |
CDC25A
|
Diagnostic Biosystems |
DCS.120+DCS.121 |
0.5 ml |
Concentrate |
CE/IVD |
MOB337-05 |
-
|
Host |
Rabbit |
Clone |
ZR394 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Urothelial carcinoma, well-differentiated liposarcoma |
Dilution |
1:100-1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment corresponding to the N-terminal of human CDK4 protein |
Localization |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
1.0 ml |
Concentrate |
RUO |
Z2750RL-R |
-
|
Host |
Rabbit |
Clone |
ZR394 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Positive control |
Urothelial carcinoma, well-differentiated liposarcoma |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Recombinant fragment corresponding to the N- terminal of human CDK4 protein. |
Localization |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
7 ml |
Ready-to-use |
RUO |
Z2750RP-R |
-
|
Host |
Rabbit |
Clone |
ZR394 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Urothelial carcinoma, well-differentiated liposarcoma |
Dilution |
1:100-1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment corresponding to the N-terminal of human CDK4 protein |
Localization |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
0.5 ml |
Concentrate |
RUO |
Z2750RS-R |
-
|
Host |
Rabbit |
Clone |
ZR394 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Urothelial carcinoma, well-differentiated liposarcomama. |
Dilution |
1:100-1:200 |
Isotype |
IgG |
Immunogen |
Recombinant fragment corresponding to the N-terminal of human CDK4 protein. |
Localization |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
0.1 ml |
Concentrate |
RUO |
Z2750RT-R |
-
|
Host |
Mouse |
Clone |
DCS-156 |
Format |
Concentrate |
Method |
F, P, WB |
Pretreatment |
Citrate |
Positive control |
Liposarcoma |
Dilution |
1:100 - 1:200 |
Isotype |
Mouse IgG1 |
Cdk4 (Cyclin dependant Kinase)
|
Zytomed Systems GmbH |
DCS-156 |
200 µl |
Concentrate |
RUO |
A03-61096 |
-
|
Host |
Mouse |
Clone |
DCS-31.2 |
Format |
Concentrate |
Method |
F, P, WB, |
Pretreatment |
Citrate |
Positive control |
Liposarkoma |
Dilution |
1:100 - 1:250 |
Isotype |
Mouse IgG1 |
Cdk4 (Cyclin dependent Kinase)
|
Zytomed Systems GmbH |
DCS-31.2 |
100 µg |
Concentrate |
RUO |
603-1840 |
-
|
Host |
Mouse |
Clone |
BC39 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Colon Carcinoma |
Dilution |
1:100 |
Isotype |
IgG1 kappa |
Localization |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3184A |
-
|
Host |
Mouse |
Clone |
BC39 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Colon Carcinoma |
Dilution |
1:100 |
Isotype |
IgG1 kappa |
Localization |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
1 ml |
Concentrate |
CE/IVD |
ACI3184C |
-
|
Host |
Mouse |
Clone |
BC39 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Colon Carcinoma |
Dilution |
- |
Isotype |
IgG1 kappa |
Localization |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
6 ml |
Ready-to-use |
CE/IVD |
API3184AA |
-
|
Host |
Mouse |
Clone |
BC39 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Colon Carcinoma |
Dilution |
- |
Isotype |
IgG1 kappa |
Localization |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3184G |
-
|
Host |
Mouse |
Clone |
AMT28 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
EDTA |
Positive control |
Colon Carcinoma |
Dilution |
- |
Isotype |
Mouse IgG1 kappa |
Localization |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
AMT28 |
6 ml |
Ready-to-use |
CE/IVD |
PDM187 |
-
|
Host |
Rabbit |
Clone |
EP25 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Colon, Colon adenocarcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
Localization |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
1 ml |
Concentrate |
CE/IVD |
RMAB059 |
-
|
Host |
Rabbit |
Clone |
EP25 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Colon, Colon adenocarcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
Localization |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB059-01 |
-
|
Host |
Rabbit |
Clone |
EP25 |
Format |
Concentrate |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Colon, Colon adenocarcinoma |
Dilution |
1:50 - 1:100 |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
Localization |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB059-05 |
-
|
Host |
Rabbit |
Clone |
EP25 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Colon, Colon adenocarcinoma |
Isotype |
Rabbit IgG |
Immunogen |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
Localization |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD059 |
-
|
Host |
Rabbit |
Clone |
ZR215 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Normal colon or colon adenocarcinoma |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 |
Immunogen |
Recombinant human full-length CDX2 protein |
Localization |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
1.0 ml |
Concentrate |
CE/IVD |
Z2494RL |
-
|
Host |
Rabbit |
Clone |
ZR215 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Positive control |
Normal colon or colon adenocarcinoma |
Dilution |
- |
Isotype |
IgG1 |
Immunogen |
Recombinant human full-length CDX2 protein |
Localization |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
7 ml |
Ready-to-use |
CE/IVD |
Z2494RP |
-
|